Biotech Venture Debt: Technical Analysis of Deal Structuring and Covenant Architecture
Current Market Dynamics and Transaction Volume
The biotech venture debt market underwent substantial transformation following the Silicon Valley Bank collapse
PIPEs in Biopharma: A 2025 Deep Dive
The biopharma sector in 2025 is navigating a difficult funding landscape. Public markets have cooled off after the boom of
Disease-Linked Bonds: Cancer Bonds and Pandemic Bonds – A Comprehensive Analysis
1. Historical Examples of Disease-Linked Bonds
Pandemic Bonds (World Bank PEF)
The most prominent example is the World Bank'
The weekly term sheet (38)
The week of September 15-20, 2025 witnessed over 40 distinct biotech pharmaceutical transactions totaling more than $6 billion in disclosed
The Great AI Wrapper Charade in Biotech
In boardrooms and biotech conferences alike, one phrase has become inescapable: “our AI-powered platform.” Startups in drug discovery, clinical decision
Company of the week: Poxel SA: Navigating Judicial Reorganization While Clinical Assets Retain Promise
Poxel SA, a French biopharmaceutical company that successfully developed and commercialized the first-in-class diabetes drug TWYMEEG® in Japan, filed for
Fund of the week: OrbiMed Royalty & Credit Opportunities
Executive Summary
OrbiMed's Royalty & Credit Opportunities strategy has emerged as a prominent non-dilutive financing platform in the
Venture Debt in Biotech & Pharma: A 2025 Comprehensive Analysis
Venture Debt in Biotech & Pharma: A 2025 Deep Dive
Introduction: The Rise of Biotech Venture Debt
Venture debt has
Pharmaceutical Royalty Structures: A Global Technical Analysis
Executive Summary
In the pharmaceutical industry, royalties serve as a fundamental mechanism for sharing value from intellectual property and products.
Lilly’s TuneLab: accelerator, equaliser—or a gilded cage?
Eli Lilly’s latest act of corporate altruism arrived in September 2025 in the form of TuneLab, an artificial intelligence
